 Ace inhibitors in macular degeneration |
| OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention ... |
|
| Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals |
| We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, ... |
|
| Novel benzylalcohol derivatives and processes for preparing the same |
| What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-... |
|
| Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents |
| What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and ... |
|
| Dihydropyridine derivatives and pharmaceutical composition thereof |
| OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (... |
|
| Use of fedotozine in the treatment of functional states of intestinal obstructions |
| We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering ... |
|
| Manufacture of pharmaceutical dosage forms |
| OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ... |
|
| Device comprising liner for protecting fluid sensitive medicament |
| OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various ... |
|
|
Medicament adsorbates and their preparation
| Details |
Inventors: Mozda, Ronald F.;
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Primary Examiner: Lusignan; Michael R.
Assistant Examiner:
Attorney, Agent or Firm: Gaglia, Jr.; Charles A., Nath; Gary M.
A medicament adsorbate and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein an edible wax and a medicament drug. |
|
DETAILED DESCRIPTION In particular, it has been found that a good tasting medicament adsorbate is produced from admixing about 1 to about 25% by weight of a medicament drug with about 8 to about 50% by weight of a melted edible wax to form a dispersion.
The dispersion is then further admixed with about 25 to about 91% by weight of a complex magnesium aluminum silicate until it is sorbed therein to form a homogenous mixture.
While the invention is not to be limited to theoretical considerations, it is believed that when the medicament drug is added to the melted wax, the medicament either dissolves in the wax and/or melts and is dispersed throughout the wax by mixing.
The complex magnesium aluminum silicate is then added to the wax-medicament solution or co-melt.
The medicament and wax are then sorbed into the complex magnesium aluminum silicate.
The wax acting as both a solvent or carrier for the medicament and as sealent after the medicament has been sorbed into the complex magnesium aluminum silicate.
The wax-medicament solution or co-melt may alternatively be added to the complex magnesium aluminum silicate with mixing.
This may be accomplished by pouring, spraying or related techniques known in the art.
It is believed that this sorbing of the hot wax-medicament solution or co-melt into the complex magnesium aluminum silicate renders the medicament not available for organoleptic taste prior to passage into the digestive tract and subsequent desorption by the gastric juice.
This taste masking sorption effect is not found in the wax medicament mixture alone.
The taste masking sorption effect of this invention is superior to the taste masking found when a medicament drug is adsorbed merely from aqueous, organic or mixed solvents onto a complex magnesium aluminum silicate.
In the practice of the present invention, the complex magnesium aluminum silicate is a standard article of commerce.
The typical average chemical analysis of complex magnesium aluminum silicate, conventionally expressed as oxides, maybe represented as follows:
______________________________________
Percent by Weight
______________________________________
Silicon dioxide
55 to 70
Magnesium oxide
2
|
| Related patents |
|
|
Sustained release formulations
We claim: 1. In combination, a drug suitable for oral delivery and a delivery system for sustained release dosage of said drug comprising: (a) a core portion containing ...
|
|
|
Water dispersible gemfibrozil compositions
What is claimed is: 1. A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax ...
|
|
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines
OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such as phenylalanine is administered concomitnatly with an indirect-acting ...
|
|
|
1-azabicycloalkane derivatives, their preparation process and their use as medicaments
What is claimed is: 1. A compound of formula (I) ##STR5## in which n represents the number 1, R.sub.1 and R.sub.2, identical or different represent hydrogen or an ...
|
|
|
Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
OF THE INVENTION The novel method of treatment of neurodegeneration of this invention comprises the administration to a patient in need of such treatment with an ...
|
|
|
Iron citrate complex, process for its production, and its pharmaceutical
We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out below: (a) average composition by weight of about: 10.6% carbon, 2.62%...
|
|
|
Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
OF INVENTION The 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles of the present invention have the formula (I) as described hereinbefore. In the formula (I), the ...
|
|
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation
The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent, said cross-linking reagent being selected ...
|
|
|
Apparatus for manufacturing granulated material
The invention proceeds from the consideration that it is not possible to reduce the width of the slit, especially at high production rates i.e., at high relative ...
|
|
|
Substituted and bridged pyridines useful as calcium channel blockers
OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## ...
|
|
|
Vasodialators 
